Skip to main content

Advertisement

SpringerLink
Log in

Why We Should Not Treat Patients with Stage II Colon Cancer

  • Adjuvant Therapy for Colon Cancers (AB Benson and A de Gramont, Section Editors)
  • Published:
Current Colorectal Cancer Reports

Abstract

Research assessing the worth of adjuvant chemotherapy for stage II colon cancer has been ongoing for several decades. The majority of studies have not demonstrated a significant improvement in survival. Despite this, many patients with stage II disease deemed to be at high-risk for recurrence do receive postoperative chemotherapy. The benefit of adjuvant therapy in such high-risk patients has been suggested by retrospective analyses of phase III trials. Molecular and genetic factors are being investigated to learn if they can predict those who might benefit most from adjuvant therapy. The results of randomized trials and pooled analyses will be reviewed to argue that the majority of stage II colon cancer patients should not receive adjuvant chemotherapy. Prospective studies addressing the benefit of adjuvant chemotherapy in high-risk patients are a high priority.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09 based on November 2011 SEER data submission, posted to the SEER web site, April, 2012

  3. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–806.

    Article  PubMed  CAS  Google Scholar 

  4. Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging handbook from the AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  5. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–4005.

    Article  PubMed  CAS  Google Scholar 

  6. • O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–8. The authors examined the SEER database and identified over 24,000 patients with stage II colon cancer. Patients with no poor prognosis features had a significantly higher 5-year survival than those with one or more poor prognosis features. The use of postoperative chemotherapy did not improve survival in either good prognosis or poor prognosis patients.

    Article  PubMed  Google Scholar 

  7. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.

    Article  Google Scholar 

  8. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7:1447–56.

    PubMed  CAS  Google Scholar 

  9. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.

    Article  PubMed  CAS  Google Scholar 

  10. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Duke’s B2 colon cancer. J Clin Oncol. 1995;13:2936–43.

    PubMed  CAS  Google Scholar 

  11. Dahl O, Oystein F, Carlsen E, et al. Initial results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisole in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol. 2009;48:368–76.

    Article  PubMed  CAS  Google Scholar 

  12. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8.

    Article  PubMed  Google Scholar 

  13. Schippinger W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97:1021–7.

    Article  PubMed  CAS  Google Scholar 

  14. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: IMPACT2: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17:1356–63.

    Google Scholar 

  15. Benson III AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.

    Article  PubMed  Google Scholar 

  16. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.

    Article  PubMed  Google Scholar 

  17. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 1 irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–80.

    Article  PubMed  CAS  Google Scholar 

  18. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.

    Article  PubMed  CAS  Google Scholar 

  19. Van Cutsem E, Labianca R, Bodoky G, et al. PETACC-3: a randomized phase III trial comparing infused irinotecan/5-fluorouracil/folinic acid with 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer. J Clin Oncol. 2009;27:3117–25.

    Article  PubMed  Google Scholar 

  20. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.

    Article  PubMed  CAS  Google Scholar 

  21. • Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:1–8. This report provides updated information on 5-year disease-free survival and 6-year survival of patients treated on the MOSAIC trial. The significant benefits observed with the addition of oxaliplatin to 5-FU/leucovorin in the overall population were derived entirely by the favorable effect in the subgroup of patients with stage III disease.

    Article  Google Scholar 

  22. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.

    Article  PubMed  CAS  Google Scholar 

  23. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664–70.

    Article  PubMed  Google Scholar 

  24. O’Connell MJ, Campbell ME, Goldberg RM, et al. Survival following recurrence in stage II and III colon cancer: finding from the ACCENT data set. J Clin Oncol. 2008;26:2336–41.

    Article  PubMed  Google Scholar 

  25. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

    Article  PubMed  CAS  Google Scholar 

  26. • Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26. This retrospective analysis found that mismatch repair deficient tumors have a better outcome than mismatch repair tumors, and that stage II patients with mismatch repair deficient tumors appear to be harmed by adjuvant therapy with bolus 5-FU given with leucovorin or levamisole.

    Article  PubMed  CAS  Google Scholar 

  27. Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer—a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29:3153–62.

    Article  PubMed  Google Scholar 

  28. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213–21.

    Article  PubMed  CAS  Google Scholar 

  29. Ogunbiyi OA, Goodfellow PJ, Herforth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol. 1998;16:427–33.

    PubMed  CAS  Google Scholar 

  30. Wang W, Li Y-F, Sun X-W. Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage II colon cancer patients. Chin J Cancer. 2010;29:761–7.

    Article  PubMed  CAS  Google Scholar 

  31. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:3153–62.

    Article  Google Scholar 

  32. Engstrom PF, Arnoletti JP, Benson 3rd AB, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Cancer Netw. 2010;8:507–9.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Oncology/Hematology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE, 68198-7680, USA

    Shanmuga P. Subbiah & Jean L. Grem

Authors
  1. Shanmuga P. Subbiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean L. Grem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean L. Grem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Subbiah, S.P., Grem, J.L. Why We Should Not Treat Patients with Stage II Colon Cancer. Curr Colorectal Cancer Rep 8, 204–209 (2012). https://doi.org/10.1007/s11888-012-0136-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-012-0136-3

Keywords

Search

Navigation